New concepts on risk factors of HPV and novel screening strategies for cervical cancer precursors

During the past several years, this author has been engaged in coordinating two major multicentre trials testing optional screening tools for cervical cancer (CC) in low-resource settings both in East Europe and in Latin America. These international trials include the NIS (New Independent States of the former Soviet Union) cohort (n = 3,187 women) and the LAMS (Latin American Screening) study (n = 12,114 women). In both studies, a sizeable cohort of women (887 and 1,011, respectively) have been prospectively followed-Lip to assess the natural history of high-risk human papillomavirus (HR-HPV) infections and the role of implicated risk factors as potential predictors of disease outcome (acquisition, persistence and clearance).

In this communication some of the key observations recently reported from the NIS and LAMS Studies will be discussed, with special emphasis on i) risk factors that are still controversial (i.e., oral contraception; OC, and smoking) or not previously studied (drug addiction), on ii) reproductive factors as potential cofactors of HPV infections in cervical carcinogenesis (i.e., age at menarche, menopause), and finally on iii) the performance of different screening strategies among young and older women. Although closely related to these topics, a detailed discussion on the dynamics of HPV infections (acquisition, persistence, clearance) and their predictive factors falls Outside the scope of this communication, because they have been extensively discussed in a series of original reports and in a recent review of the author in this journal.

The NIS cohort failed to establish OC as a risk factor of CC. In 211 future studies, the strong confounding effects from the lifestyle behavioural factors must be taken into account, while interpreting the data on OCs as potential risk factors of CC. Similarly, it now seems that the increased risk (if any) of CC among smokers seems to be attributed to the increased acquisition of HR-HPV infections, of which the smoking status is an independent predictor in a multivariate model. The same seems to apply to drug addiction as a risk factor of CC as well. The recent LAMS data show that drug abuse itself is not a risk factor of i) contracting HR-HPV infection or ii) developing high-grade CIN. Instead, drug abuse seems to be closely associated with several of the indicators of risky sexual behaviour, which predisposes the women to oncogenic HPV infections and thus indirectly contributes to the development of CIN2+ lesions.

Data from the NIS cohort clearly implicate that menarche age is not associated with increased risk of HR-HPV infection, or development of high-grade CIN, feasibly explained by the fact that menarche age does not have any effect on the Outcome of CIN lesions or HR-HPV infections in a longitudinal setting. Another special group are postmenopausal women, recently shown to have a second peak of HR-HPV prevalence in many Populations. The NIS cohort data suggest that among women who fail to eradicate their HR-HPV infection by menopause, there is i) a transition from Multiple infections to single-type infections, and ii) selection of an integrated viral clone has already taken place, driving the process towards an aggressively progressing cervical disease.

Finally, these special features of HR-HPV infections among younger and older women lead us to consider, whether different screening strategies are needed for younger and older women. Consonant with other recent reports, data from the LAMS Study show that conventional Pap and HC2, but not LBC and VIA, perform significantly differently among younger and older women. However, the choice of an optimal screening test for Young and older women depends on whether the highest positive predictive value (PPV) (Pap test) or the best balance between sensitivity and specificity (SE/SP) (HC2) is used as the selection criteria.

Both the NIS cohort and LAMS Study have significantly contributed to solving several of the open issues in the natural history of HR-HPV infections, including their risk factors, covariates necessary in cervical carcinogenesis as well as in sorting Out the optional screening strategies in low-resource settings and for women in different age groups. In the long run, it is most likely that the cost-effectiveness will be the decisive factor for which screening tests will be selected. Needless to reiterate that screening for cervical cancer precursors will be mandatory until the foreseeable future, even in this emerging era of prophylactic HPV vaccination.

Human papillomavirus; Risk factors; Covariates; Oral contraception; Smoking; Drug addiction; Reproductive factors; Menarche; Menopause; Screening strategies; CIN; Cervical cancer

[1] Östor A.G.: “Natural history of cervical intraepithelial neoplasia - a critical review”. Int. J. Gynecol. Pathol., 1993, 12, 186.

[2] Syrjänen K.: “Natural history of cervical HPV infections and CIN”. Chapter 6. In: Syrjänen K. and Syrjänen S. “Papillomavirus Infections in Human Pathology”. J. Wiley & Sons, New York, 2000, 142.

[3] IARC Monographs on the evaluation of carcinogenic risks to humans. Volume 64. Papillomavirusus. Lyon. IARC, 1995, 1.

[4] Syrjänen K., Syrjänen S.: “Papillomavirus Infections in Human Pathology”. New York. J. Wiley & Sons, 2000, 1.

[5] zur Hausen H.: “Cervical carcinoma and human papillomavirus: on the road to preventing a major human cancer”. J. Natl. Cancer Inst., 2001, 93, 252.

[6] Bosch F.X., Munoz N.: “The viral etiology of cervical cancer”. Virus. Res., 2002, 89, 183.

[7] Syrjänen K.J.: “Natural history of HPV infections: recent developments”. In: Monsonego J. (ed). 5th International Multidisciplinary Congress EUROGIN 2003. Monduzi Editore, Milano 2003, 1.

[8] Ferenczy A., Franco E.: “Persistent human papillomavirus infection and cervical neoplasia”. Lancet Oncol., 2003, 3, 11.

[9] Cuzick J., Sasieni P.: “Natural history of cervical human papillomavirus”. Lancet, 2001, 358, 1550.

[10] Duggan M.A.: “A review of the natural history of cervical intraepithelial neoplasia”. Gan To Kagaku Ryoho, 2002, 29 (suppl. 1), 176.

[11] Paraskevaidis E., Kaponis A., Malamou-Mitsi V., Davidson E.J., Hirsch P.M., Koliopoulos G.: “The natural history of HPV infection of the uterine cervix. Long-term observational and histological data”. Anticancer Res., 2002, 22, 1177.

[12] Franco E.L., Villa L.L., Sobrinho J.P., Prado J.M., Rousseau M.C., Desy M.: “Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer”. J. Infect. Dis., 1999, 180, 1415.

[13] Giuliano A.R., Harris R., Sedjo R.L., Baldwin S., Roe D., Papenfuss M.R. et al.: “Incidence, prevalence, and clearance of type-specific human papillomavirus infections: The Young Women's Health Study”. J. Infect. Dis., 2002, 186, 462.

[14] Sellors J.W., Karwalajtys T.L., Kaczorowski J., Mahony J.B., Lytwyn A., Chong S. et al.: “Incidence, clearance and predictors of human papillomavirus infection in women”. CMAJ, 2003, 168, 421.

[15] Syrjänen S., Shabalova I.P., Petrovichev N., Kozachenko V.P., Zakharova T., Pajanidi A. et al.: “Acquisition of incident high-risk human papillomavirus (HPV) DNA and Pap smear abnormalities in a cohort of women subjected to HPV screening in the New Independent States (NIS) of the former Soviet Union”. J. Clin. Microbiol., 2004, 42, 505.

[16] Nobbenhuis M.A., Helmerhorst T.J., van den Brule A.J., Rozendaal L., Voorhorst F.J., Bezemer P.D. et al.: “Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear”. Lancet, 2001, 358, 1782.

[17] Schiffman M., Wheeler C.M., Castle P.E.: “Human papillomavirus DNA remains detectable longer than related cervical cytologic abnormalities”. J. Infect. Dis., 2002, 186, 1169.

[18] Nobbenhuis M.A., Helmerhorst T.J., van den Brule A.J., Rozendaal L., Bezemer P.D., Voorhorst F.J. et al.: “High-risk human papillomavirus clearance in pregnant women: trends for lower clearance during pregnancy with a catch-up postpartum”. Br. J. Cancer, 2002, 87, 75.

[19] Giuliano A.R., Sedjo R.L., Roe D.J., Harri R., Baldwi S., Papenfuss M.R.: “Clearance of oncogenic human papillomavirus (HPV) infection: effect of smoking (United States)”. Cancer Causes Control., 2002, 13, 839.

[20] Zielinski D.G., Snijders P.J., Rozendaal L., Voorhorst F.J., Runsink A.P., de Schipper F.A., Meijer C.J.: “High-risk HPV testing in women with borderline and mild dyskaryosis: long-term follow-up data and clinical relevance”. J. Pathol., 2001, 195, 300.

[21] Syrjänen S., Shabalova I.P., Petrovichev N., Kozachenko V.P., Zakharova T., Pajanidi A. et al.: “Clearance of high-risk human papillomavirus (HPV) DNA and Pap smear abnormalities in a cohort of women subjected to HPV screening in the New Independent States (NIS) of the former Soviet Union”. Eur. J. Gynecol. Obstet. Reprod. Biol., 2005, 119, 219.

[22] Syrjänen K., Gissmann L., Koss L.G. (eds.). Papillomaviruses and Human Disease. Springer Verlag, Berlin, Heidelberg, 1987, 1.

[23] Cavalcanti S.M., Zardo L.G., Passos M.R., Oliveira L.H.: “Epidemiological aspects of human papillomavirus infection and cervical cancer in Brazil”. J. Infect., 2000, 40, 80.

[24] Trottier H., Franco E.L.: “The epidemiology of genital human papillomavirus infection”. Vaccine, 2006, 24 (suppl. 1), S1.

[25] Castellsague X., Munoz N.: “Cofactors in human papillomavirus carcinogenesis-role of parity, oral contraceptives, and tobacco smoking”. J. Natl. Cancer Inst. Monogr., 2003, 20.

[26] Kataja V., Syrjänen S., Yliskoski M., Hippeläinen M., Väyrynen M., Saarikoski S. et al.: “Risk factors associated with cervical human papillomavirus infections: a case-control study”. Am. J. Epidemiol., 1993, 138, 735.

[27] Munoz N., Bosch F.X., de Sanjose S., Herrero R., Castellsague X., Shah K.V. et al.: “Epidemiologic classification of human papillomavirus types associated with cervical cancer”. N. Engl. J. Med., 2003, 348, 518.

[28] Campo S. (ed.). Papillomavirus Research: From Natural History to Vaccines and Beyond. Caister Academic Press, Norwich, UK, 2006, 1.

[29] Syrjänen K., Väyrynen M., Castren O., Yliskoski M., Mäntyjärvi R., Pyrhönen S., Saarikoski S.: “Sexual behaviour of women with human papillomavirus (HPV) lesions of the uterine cervix”. Br. J. Vener. Dis., 1984, 60, 243.

[30] Reeves W.C., Rawls W.E., Brinton L.A.: “Epidemiology of genital papillomaviruses and cervical cancer”. Rev. Infect. Dis., 1989, 11, 426.

[31] Rieck G., Fiander A.: “The effect of lifestyle factors on gynaecological cancer”. Best. Pract. Res. Clin. Obstet. Gynaecol., 2006, 20, 227.

[32] Kjellberg L., Hallmans G., Ahren A.M., Johansson R., Bergman F., Wadell G. et al.: “Smoking, diet, pregnancy and oral contraceptive use as risk factors for cervical intra-epithelial neoplasia in relation to human papillomavirus infection”. Br. J. Cancer, 2000, 82, 1332.

[33] Vaccarella S., Herrero R., Dai M., Snijders P.J., Meijer C.J., Thomas J.O. et al.: “Reproductive factors, oral contraceptive use, and human papillomavirus infection: pooled analysis of the IARC HPV prevalence surveys”. Cancer Epidemiol. Biomarkers Prev., 2006, 15, 2148.

[34] Castle P.E., Walker J.L., Schiffman M., Wheeler C.M.: “Hormonal contraceptive use, pregnancy and parity, and the risk of cervical intraepithelial neoplasia 3 among oncogenic HPV DNA-positive women with equivocal or mildly abnormal cytology”. Int. J. Cancer, 2005, 117, 1007.

[35] Vaccarella S., Franceschi S., Herrero R., Munoz N., Snijders P.J., Clifford G.M. et al.: “Sexual behavior, condom use, and human papillomavirus: pooled analysis of the IARC human papillomavirus prevalence surveys”. Cancer Epidemiol. Biomarkers. Prev., 2006, 15, 326.

[36] IARC. IARC monographs on the evaluation of carcinogenic risks to humans. Volume 72. Hormonal contraception and postmenopausal hormonal therapy. Lyon, IARC Press, 1999, 1.

[37] Moreno V., Bosch F.X., Munoz N., Meijer C.J., Shah K.V., Walboomers J.M., Herrero R., Franceschi S.: “Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study”. Lancet, 2002, 359, 1085.

[38] Green J., Berrington de Gonzalez A., Smith J.S., Franceschi S., Appleby P., Plummer M., Munoz N.: “Human papillomavirus infection and use of oral contraceptives”. Br. J. Cancer, 2003, 88, 1713.

[39] Syrjänen S., Shabalova I.P., Petrovichev N., Kozachenko V.P., Zakharova T., Pajanidi A. et al.: “Oral contraceptives are not an independent risk factor for cervical intraepithelial neoplasia or high-risk human papillomavirus infections”. Anticancer Res., 2006, 26, 4729.

[40] Hildesheim A., Herrero R., Castle P.E., Wacholder S., Bratti M.C., Sherman M.E. et al.: “HPV co-factors related to the development of cervical cancer: results from a population-based study in Costa Rica”. Br. J. Cancer, 2001, 84, 1219.

[41] Giuliano A.R., Papenfuss M., Abrahamsen M., Denman C., de Zapien J.G., Henze J.L. et al.: “Human papillomavirus infection at the United States-Mexico border: implications for cervical cancer prevention and control”. Cancer Epidemiol. Biomarkers Prev., 2001, 10, 1129.

[42] Peyton C.L., Gravitt P.E., Hunt W.C., Hundley R.S., Zhao M., Apple R.J. et al.: “Determinants of genital human papillomavirus detection in a US population”. J. Infect. Dis., 2001, 183, 1554.

[43] Herrero R., Castle P.E., Schiffman M., Bratti M.C., Hildesheim A., Morales J. et al.: “Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica”. J. Infect. Dis., 2005, 191, 1796.

[44] Kahn J.A., Rosenthal S.L., Succop P.A., Ho G.Y., Burk R.D.: “Mediators of the association between age of first sexual intercourse and subsequent human papillomavirus infection”. Pediatrics, 2002, 109, E5.

[45] Munoz N., Franceschi S., Bosetti C., Moreno V., Herrero R., Smith J.S. et al.: “Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study”. Lancet, 2002, 359, 1093.

[46] Deacon J.M., Evans C.D., Yule R., Desai M., Binns W., Taylor C. et al.: “Sexual behaviour and smoking as determinants of cervical HPV infection and of CIN3 among those infected: a case-control study nested within the Manchester cohort”. Br. J. Cancer, 2000, 83, 1565.

[47] Smith E.M., Ritchie J.M., Levy B.T., Zhang W., Wang D., Haugen T.H. et al.: “Prevalence and persistence of human papillomavirus in postmenopausal age women”. Cancer Detect. Prev., 2003, 27, 472.

[48] Winer R.L., Koutsky L.A.: “Human Papillomavirus through the ages”. J. Infect. Dis., 2005, 191, 1787.

[49] ter Meulen J., Eberhardt H.C., Luande J., Mgaya H.N., Chang-Claude J., Mtiro H. et al.: “Human papillomavirus (HPV) infection, HIV infection and cervical cancer in Tanzania, east Africa”. Int. J. Cancer, 1992, 51, 515.

[50] Collins S.I., Mazloomzadeh S., Winter H., Rollason T.P., Blomfield P., Young L.S. et al.: “Proximity of first intercourse to menarche and the risk of human papillomavirus infection: a longitudinal study”. Int. J. Cancer, 2005, 114, 498.

[51] Miller A.B., Nazeer S., Fonn S., Brandup-Lukanow A., Rehman R., Cronje H. et al.: “Report on Consensus Conference on Cervical Cancer Screening and Management”. Int. J. Cancer, 2000, 86, 440.

[52] Hakama M.: “Screening for cervical cancer: Experience from the Nordic Countries”. In: Franco E., Monsonego J. (eds.). New Developments in Cervical Cancer Screening and Prevention. Oxford, Blackwell Science, 1997, 190.

[53] Monsonego J.: “HPV infections and cervical cancer prevention. Priorities and new directions”. Gynecol. Oncol., 2005, 96, 830.

[54] Monsonego J., Bosch F.X., Coursaget P., Cox J.T., Franco E., Frazer I. et al.: “Cervical cancer control, priorities and new directions”. Int. J. Cancer, 2004, 108, 329.

[55] Wright T.C. Jr., Schiffman M., Solomon D., Cox J.T., Garcia F., Goldie S. et al.: “Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening”. Obstet. Gynecol., 2004, 103, 304.

[56] Ferris D.G.: “The 2001 ASCCP management guidelines for cervical cytology”. Am. Fam. Physician., 2004, 70, 1866.

[57] Cox T., Cuzick J.: “HPV DNA testing in cervical cancer screening: from evidence to policies”. Gynecol. Oncol., 2006, 103, 8.

[58] Franco E.L., Bosch F.X., Cuzick J., Schiller J.T., Garnett G.P., Meheus A. et al.: “Knowledge gaps and priorities for research on prevention of HPV infection and cervical cancer”. Vaccine, 2006, 24 (suppl. 3), S242.

[59] Cuzick J., Beverley E., Ho L., Terry G., Sapper H., Mielzynska I. et al.: “HPV testing in primary screening of older women”. Br. J. Cancer, 1999, 81, 554.

[60] Clavel C., Masure M., Bory J.P., Putaud I., Mangeonjean C., Lorenzato M. et al.: “Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women”. Br. J. Cancer, 2001, 84, 1616.

[61] Duttagupta C., Sengupta S., Roy M., Sengupta D., Chakraborty S., Bhattacharya P. et al.: “Oncogenic human papillomavirus (HPV) infection and uterine cervical cancer: a screening strategy in the perspective of rural India”. Eur. J. Cancer Prev., 2002, 11, 447.

[62] Goldie S.J., Kim J.J., Wright T.C.: “Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more”. Obstet. Gynecol., 2004, 103, 619.

[63] Syrjänen S., Shabalova I.P., Petrovichev N., Kozachenko V.P., Zakharova T., Pajanidi A. et al.: “Human Papillomavirus testing and conventional Pap smear cytology as optional screening tools of women at different risk for cervical cancer in countries of former Soviet Union”. J. Lower Genital Tract. Dis., 2002, 6, 97.

[64] Syrjänen K., Naud P., Derchain S.M., Roteli-Martins C., Longatto-Filho A., Tatti S. et al.: “Comparing Pap smear cytology, aided visual inspection, screening colposcopy, cervicography and HPV testing as optional screening tools in Latin America. Study design and baseline data of the LAMS Study”. Anticancer Res., 2005, 25, 3469.

[65] Syrjänen S., Shabalova I.P., Petrovichev N., Kozachenko V.P., Zakharova T., Pajanidi A. et al.: “Acquisition of incident high-risk human papillomavirus (HPV) DNA and Pap smear abnormalities in a cohort of women subjected to HPV sreening in the New Independent States (NIS) of the Former Soviet Union”. J. Clin. Microbiol., 2004, 42, 505.

[66] Syrjänen S., Shabalova I.P., Petrovichev N., Kozachenko V.P., Zakharova T., Pajanidi A. et al.: “Factors predicting persistence of high-risk human papillomavirus (HPV) infections in women prospectively followed-up in three New Independent States (NIS) of the Former Soviet Union”. Eur. J. Gynaecol. Oncol., 2005, 26, 491.

[67] Syrjänen S., Shabalova I.P., Petrovichev N., Kozachenko V.P., Zakharova T., Pajanidi A.: “Age-specific incidence and clearance of high-risk human papillomavirus infections in women in the former Soviet Union”. Int. J. STD AIDS, 2005, 16, 217.

[68] Syrjänen K.J.: “Mechanisms and predictors of high-risk human papillomavirus (HPV) clearance in the uterine cervix”. Eur. J. Gynecol. Oncol., 2007, 28, 337.

[69] Sperling M.A.: “Complications of systemic oral contraceptive therapy: neoplasm - breast, uterus, cervix and vagina”. West. J. Med. Surg., 1975, 122, 42.

[70] Singer A., Shearman R.P., Scott G.C.: “Contraceptives and cervical carcinoma”. Br. Med. J., 1969, 4, 108.

[71] Boyce J.G., Lu T., Nelson J.H. Jr., Fruchter R.G.: “Oral contraceptives and cervical carcinoma”. Am. J. Obstet. Gynecol., 1977, 128, 761.

[72] Robert H.G., Dupre-froment J.: “Of the cervix intra-epithelial cancer in pill users and non-users”. Contracept. Fertil. Sex (Paris), 1979, 7, 9.

[73] Peters R.K., Thomas D., Hagan D.G., Mack T.M., Henderson B.E.: “Risk factors for invasive cervical cancer among Latinas and non-Latinas in Los Angeles County”. J. Natl. Cancer Inst., 1986, 77, 1063.

[74] Negrini B.P., Schiffman M.H., Kurman R.J., Barnes W., Lannom L., Malley K. et al.: “Oral contraceptive use, human papillomavirus infection, and risk of early cytological abnormalities of the cervix”. Cancer Res., 1990, 50, 4670.

[75] Zondervan K.T., Carpenter L.M., Painter R., Vessey M.P.: “Oral contraceptives and cervical cancer-further findings from the Oxford Family Planning Association contraceptive study”. Br. J. Cancer, 1996, 73, 1291.

[76] Daling J.R., Madeleine M.M., McKnight B., Carter J.J., Wipf G.C., Ashley R. et al.: “The relationship of human papillomavirus-related cervical tumors to cigarette smoking, oral contraceptive use, and prior herpes simplex virus type 2 infection”. Cancer Epidemiol. Biomarkers Prev., 1996, 5, 541.

[77] Castle P.E., Wacholder S., Lorincz A.T., Scott D.R., Sherman M.E., Glass A.G. et al.: “A prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women”. J. Natl. Cancer Inst., 2002, 94, 1406.

[78] Shapiro S., Rosenberg L., Hoffman M., Kelly J.P., Cooper D.D., Carrara H. et al.: “Risk of invasive cancer of the cervix in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen oral contraceptives (South Africa)”. Cancer Causes Control., 2003, 14, 485.

[79] Shields T.S., Brinton L.A., Burk R.D., Wang S.S., Weinstein S.J., Ziegler R.G. et al.: “A case-control study of risk factors for invasive cervical cancer among U.S. women exposed to oncogenic types of human papillomavirus”. Cancer Epidemiol. Biomarkers Prev., 2004, 13, 1574.

[80] Hammouda D., Munoz N., Herrero R., Arslan A., Bouhadef A., Oublil M. et al.: “Cervical carcinoma in Algiers, Algeria: human papillomavirus and lifestyle risk factors”. Int. J. Cancer, 2005, 113, 483.

[81] Thiry L., Vokaer R., Detremmerie O., De Schepper N., Herzog A., Bollen A.: “Cancer of the cervix, papillomavirus, contraception and tobacco”. J. Gynecol. Obstet. Biol. Reprod. (Paris), 1993, 22, 477.

[82] Lacey J.V., Jr., Brinton L.A., Abbas F.M., Barnes W.A., Gravitt P.E., Greenberg M.D. et al.: “Oral contraceptives as risk factors for cervical adenocarcinomas and squamous cell carcinomas”. Cancer Epidemiol. Biomarkers Prev., 1999, 8, 1079.

[83] Hildesheim A., Hadjimichael O., Schwartz P.E., Wheeler C.M., Barnes W., Lowell D.M. et al.: “Risk factors for rapid-onset cervical cancer”. Am. J. Obstet. Gynecol., 1999, 180, 571.

[84] Kjellberg L., Hallmans G., Ahren A.M., Johansson R., Bergman F., Wadell G. et al.: “Smoking, diet, pregnancy and oral contraceptive use as risk factors for cervical intra-epithelial neoplasia in relation to human papillomavirus infection”. Br. J. Cancer, 2000, 82, 1332.

[85] Hildesheim A., Herrero R., Castle P.E., Wacholder S., Bratti M.C., Sherman M.E. et al.: “HPV cofactors related to the development of cervical cancer: results from a population-based study in Costa Rica”. Br. J. Cancer, 2001, 84, 1219.

[86] Coker A.L., Sanders L.C., Bond S.M., Gerasimova T., Pirisi L.: “Hormonal and barrier methods of contraception, oncogenic human papillomaviruses, and cervical squamous intraepithelial lesion development”. J. Womens Health Gend Based Med., 2001, 10, 441.

[87] Silins I., Wang X., Tadesse A., Jansen K.U., Schiller J.T., Avall-Lundqvist E. et al.: “A population-based study of cervical carcinoma and HPV infection in Latvia”. Gynecol. Oncol., 2004, 93, 484.

[88] Hannaford P.C.: “Cervical cancer and methods of contraception”. Adv. Contracept., 1991, 7, 317.

[89] Bosch F.X., Munoz N., de Sanjose S., Izarzugaza I., Gili M., Viladiu P. et al.: “Risk factors for cervical cancer in Colombia and Spain”. Int. J. Cancer, 1992, 52, 750.

[90] Kjaer S.K., Engholm G., Dahl C., Bock J.E., Lynge E., Jensen O.M.: “Case-control study of risk factors for cervical squamous-cell neoplasia in Denmark. III. Role of oral contraceptive use”. Cancer Causes Control., 1993, 4, 513.

[91] Brisson J., Morin C., Fortier M., Roy M., Bouchard C., Leclerc J. et al.: “Risk factors for cervical intraepithelial neoplasia: differences between low- and high-grade lesions”. Am. J. Epidemiol., 1994, 140, 700.

[92] Ylitalo N., Sorensen P., Josefsson A., Frisch M., Sparen P., Ponten J. et al.: “Smoking and oral contraceptives as risk factors for cervical carcinoma in situ”. Int. J. Cancer, 1999, 81, 357.

[93] Matos A., Moutinho J., Pinto D., Medeiros R.: “The influence of smoking and other cofactors on the time to onset to cervical cancer in a southern European population”. Eur. J. Cancer Prev., 2005, 14, 485.

[94] Eluf-Neto J., Booth M., Munoz N., Bosch F.X., Meijer C.J., Walboomers J.M.: “Human papillomavirus and invasive cervical cancer in Brazil”. Br. J. Cancer, 1994, 69, 114.

[95] Munoz N., Bosch F.X., de Sanjose S., Shah K.V.: “The role of HPV in the etiology of cervical cancer”. Mutat. Res., 1994, 305, 293.

[96] Santos C., Munoz N., Klug S., Almonte M., Guerrero I., Alvarez M. et al.: “HPV types and cofactors causing cervical cancer in Peru”. Br. J. Cancer, 2001, 85, 966.

[97] Deacon J.M., Evans C.D., Yule R., Desai M., Binns W., Taylor C. et al.: “Sexual behaviour and smoking as determinants of cervical HPV infection and of CIN3 among those infected: a case-control study nested within the Manchester cohort”. Br. J. Cancer, 2000, 83, 1565.

[98] Ley C., Bauer H.M., Reingold A., Schiffman M.H., Chambers J.C., Tashiro C.J. et al.: “Determinants of genital human papillomavirus infection in young women”. J. Natl. Cancer Inst., 1991, 83, 997.

[99] Gitsch G., Kainz C., Studnicka M., Reinthaller A., Tatra G., Breitenecker G.: “Oral contraceptives and human papillomavirus infection in cervical intraepithelial neoplasia”. Arch. Gynecol. Obstet., 1992, 252, 25.

[100] Johnson T.L., Joseph C.L., Caison-Sorey T.J., Smith R.E., Bedrossian C.W., Sarkar F.H.: “Prevalence of HPV 16 and 18 DNA sequences in CIN III lesions of adults and adolescents”. Diagn. Cytopathol., 1994, 10, 276.

[101] Hildesheim A., Reeves W.C., Brinton L.A., Lavery C., Brenes M., de la Guardia M.E. et al.: “Association of oral contraceptive use and human papillomaviruses in invasive cervical cancers”. Int. J. Cancer, 1990, 45, 860.

[102] Sikström B., Hellberg D., Nilsson S., Brihmer C., Mårdh P.A.: “Contraceptive use and reproductive history in women with cervical human papillomavirus infection”. Adv. Contracept., 1995, 11, 273.

[103] Rousseau M.C., Franco E.L., Villa L.L., Sobrinho J.P., Termini L., Prado J.M. et al.: “A cumulative case-control study of risk factor profiles for oncogenic and nononcogenic cervical human papillomavirus infections”. Cancer Epidemiol. Biomarkers Prev., 2000, 9, 469.

[104] Sanchez-Aleman M.A., Uribe-Salas F., Conde-Gonzalez C.J.: “Human papillomavirus infection, a possible biological marker of sexual behavior among university students”. Salud Publica Mex, 2002, 44, 442.

[105] Molano M., Posso H., Weiderpass E., van den Brule A.J., Ronderos M., Franceschi S. et al.: “Prevalence and determinants of HPV infection among Colombian women with normal cytology”. Br. J. Cancer, 2002, 87, 324.

[106] del Amo J., Gonzalez C., Losana J., Clavo P., Munoz L., Ballesteros J. et al.: “Influence of age and geographical origin in the prevalence of high risk human papillomavirus in migrant female sex workers in Spain”. Sex. Transm. Infect., 2005, 81, 79.

[107] Moscicki A.B., Palefsky J., Gonzales J., Schoolnik G.K.: “Human papillomavirus infection in sexually active adolescent females: prevalence and risk factors”. Pediatr. Res., 1990, 28, 507.

[108] Smith E.M., Johnson S.R., Jiang D., Zaleski S., Lynch C.F., Brundage S. et al.: “The association between pregnancy and human papilloma virus prevalence”. Cancer Detect. Prev., 1991, 15, 397.

[109] Veress G., Csiky-Meszaros T., Czegledy J., Gergely L.: “Oral contraceptive use and human papillomavirus infection in women without abnormal cytological results”. Med. Microbiol. Immunol. (Berl.), 1992, 181, 181.

[110] Cavalcanti S.M., Deus F.C., Zardo L.G., Frugulhetti I.C., Oliveira L.H.: “Human papillomavirus infection and cervical cancer in Brazil: a retrospective study”. Mem. Inst. Oswaldo Cruz., 1996, 91, 433.

[111] Diakomanolis E., Elsheikh A., Voulgaris Z., Rodolakis A., Vlachos G., Michalas S.: “Cervical intraepithelial neoplasia in the young female. Diagnosis and management”. Eur. J. Gynaecol. Oncol., 2001, 22, 236.

[112] Green J., Berrington de Gonzalez A., Smith J.S., Franceschi S., Appleby P., Plummer M. et al.: “Human papillomavirus infection and use of oral contraceptives”. Br. J. Cancer, 2003, 88, 1713.

[113] Beby-Defaux A., Bourgoin A., Ragot S., Battandier D., Lemasson J.M., Renaud O. et al.: “Human papillomavirus infection of the cervix uteri in women attending a health examination center of the French social security”. J. Med. Virol., 2004, 73, 262.

[114] Munoz N., Kato I., Bosch F.X., Eluf-Neto J., de Sanjose S., Ascunce N. et al.: “Risk factors for HPV DNA detection in middle-aged women”. Sex. Transm. Dis., 1996, 23, 504.

[115] Giuliano A.R., Papenfuss M., Schneider A., Nour M., Hatch K.: “Risk factors for high-risk type human papillomavirus infection among Mexican-American women”. Cancer Epidemiol. Biomarkers Prev., 1999, 8, 615.

[116] Ho G.Y., Studentsov Y., Hall C.B., Bierman R., Beardsley L., Lempa M. et al.: “Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles”. J. Infect. Dis., 2002, 186, 737.

[117] Boardman L.A., Stanko C., Weitzen S., Sung C.J.: “Atypical squamous cells of undetermined significance: human papillomavirus testing in adolescents”. Obstet. Gynecol., 2005, 105, 741.

[118] IARC. IARC monographs on the evaluation of carcinogenic risks to humans. Volume 91. Combined estroge-progestogen contraceptives and combined estrogen-progestagen menopausal therapy. IARC Press, Lyon, 2008.

[119] Moreno V., Bosch F.X., Munoz N., Meijer C.J., Shah K.V., Walboomers J.M. et al.: “Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study”. Lancet, 2002, 359, 1085.

[120] Skegg D.C.: “Oral contraceptives, parity, and cervical cancer”. Lancet, 2002, 359, 1080.

[121] Smith J.S., Green J., Berrington de Gonzalez A., Appleby P., Peto J., Plummer M. et al.: “Cervical cancer and use of hormonal contraceptives: a systematic review”. Lancet, 2003, 361, 1159.

[122] Moodley J.: “Combined oral contraceptives and cervical cancer”. Curr. Opin. Obstet. Gynecol., 2004, 16, 27.

[123] Syrjänen S., Shabalova I.P., Petrovichev N., Kozachenko V.P., Zakharova T., Pajanidi A. et al.: “Sexual habits and human papillomavirus (HPV) infections among women in three new independent states of the former Soviet Union”. Sex. Transm. Dis., 2003, 30, 680.

[124] Syrjänen K.J., Shabalova I.P., Petrovichev N., Kozachenko V.P., Zakharova T., Pajanidi A. et al.: “Oral contraceptives arenot an independent risk factor for cervical intraepithelial neoplasia or high-risk human papillomavirus infections”. Anticancer Res., 2006, 26, 4729.

[125] Clarke E.A., Morgan R.W., Newman A.M.: “Smoking as a risk factor in cancer of the cervix additional evidence from a case control study”. Am. J. Epidemiol., 1982, 115, 59.

[126] Hellberg D., Valentin J., Nilsson S.: “Smoking as risk factor in cervical neoplasia”. Lancet, 1983, 1, 1.

[127] Brinton L.A., Schairer C., Haenszel W., Stolley P., Lehman H.F., Levine R. et al.: “Cigarette smoking and invasive cervical cancer”. JAMA, 1986, 255, 3265.

[128] Barton S.E., Maddox P.H., Jenkins D., Edwards R., Cuzick J., Singer A.: “Effect of cigarette smoking on cervical epithelial immunity: a mechanism for neoplastic change?”. Lancet, 1988, 2, 652.

[129] Layde P.M.: “Smoking and cervical cancer: cause or coincidence?”. JAMA, 1989, 261, 1631.

[130] Borck K.E., MacLennan R., Brinton L.A. et al.: “Smoking and infection agents and risk of in situ cervical cancer in sydn ey australia”. Cancer Res., 1989, 49, 4825.

[131] Winkelstein W.: “Smoking and cervical cancer - current status: a review”. Am. J. Epidemiol., 1990, 131, 945.

[132] Brinton L.: “Editorial commentary: smoking and cervical cancer-current status”. Am. J. Epidemiol., 1990, 131, 958.

[133] Hakama M., Luostarinen T., Hallmans G., Jellum E., Koskela P., Lehtinen M. et al.: “Joint effect of HPV16 with Chlamydia trachomatis and smoking on risk of cervical cancer: antagonism or misclassification (Nordic countries)”. Cancer Causes Control., 2000, 11, 783.

[134] Olsen A.O., Dillner J., Skrondal A., Magnus P.: “Combined effect of smoking and human papillomavirus type 16 infection in cervical carcinogenesis”. Epidemiology, 1998, 9, 346.

[135] Derchain S.F., Roteli-Martins C.M., Syrjanen K.J., de Abreu H.J., Martinez E.Z., Alves V.A.: “Association of oncogenic human papillomavirus DNA with high grade cervical intraepithelial neoplasia: the role of cigarette smoking”. Sex. Transm. Infect., 1999, 75, 406.

[136] Lacey J.V., Jr., Frisch M., Brinton L.A., Abbas F.M., Barnes W.A., Gravitt P.E. et al.: “Associations between smoking and adenocarcinomas and squamous cell carcinomas of the uterine cervix (United States)”. Cancer Causes Control., 2001, 12, 153.

[137] Coker A.L., Bond S.M., Williams A., Gerasimova T., Pirisi L.: “Active and passive smoking, high-risk human papillomaviruses and cervical neoplasia”. Cancer Detect. Prev., 2002, 26, 121.

[138] Haverkos H.W., Soon G., Steckley S.L., Pickworth W.: “Cigarette smoking and cervical cancer: Part I: a meta-analysis”. Biomed. Pharmacother., 2003, 57, 67.

[139] Harris T.G., Kulasingam S.L., Kiviat N.B., Mao C., Agoff S.N., Feng Q. et al.: “Cigarette smoking, oncogenic human papillomavirus, Ki-67 antigen, and cervical intraepithelial neoplasia”. Am. J. Epidemiol., 2004, 159, 834.

[140] McIntyre-Seltman K., Castle P.E., Guido R., Schiffman M., Wheeler C.M.: “Smoking is a risk factor for cervical intraepithelial neoplasiagrade 3 among oncogenic human papillomavirus DNA-positive women with equivocal or mildly abnormal cytology”. Cancer Epidemiol. Biomarkers Prev., 2005, 14, 1165.

[141] Tolstrup J., Munk C., Thomsen B.L., Svare E., Brule A.J., Gronbaek M. et al.: “The role of smoking and alcohol intake in the development of high-grade squamous intraepithelial lesions among high-risk HPV-positive women”. Acta Obstet. Gynecol. Scand., 2006, 85, 1114.

[142] Gunnell A.S., Tran T.N., Torrang A., Dickman P.W., Sparen P., Palmgren J. et al.: “Synergy between cigarette smoking and human papillomavirus Type 16 in cervical cancer in situ development”. Cancer Epidemiol. Biomarkers Prev., 2006, 15, 2141.

[143] Plummer M., Herrero R., Franceschi S., Meijer C.J., Snijders P., Bosch F.X. et al.: “Smoking and cervical cancer: pooled analysis of the IARC multi-centric case-control study”. Cancer Causes Control., 2003, 14, 805.

[144] Ho G.Y., Kadish A.S., Burk R.D., Basu J., Palan P.R., Mikhail M. et al.: “HPV 16 and cigarette smoking as risk factors for high-grade cervical intra-epithelial neoplasia”. Int. J. Cancer, 1998, 78, 281.

[145] Acladious N.N., Sutton C., Mandal D., Hopkins R., Zaklama M., Kitchener H.: “Persistent human papillomavirus infection and smoking increase risk of failure of treatment of cervical intraepithelial neoplasia (CIN)”. Int. J. Cancer, 2002, 98, 435.

[146] Syrjänen K.J., Shabalova I.P., Petrovichev N., Kozachenko V.P., Zakharova T., Pajanidi A. et al.: “Smoking is an independent risk factor for oncogenic human papillomavirus (HPV) infections but not high-grade CIN”. Eur. J. Epidemiol., 2007, 22, 723.

[147] Marzo Lopez M.C., Aguilar Ligorit E., Ramirez Bosca A., Montolio Donate S., Soto Ferrando P., Castells Rodellas A.: “Study of immunologic parameters in parenteral drug addicts (PDA) with condylomata acuminata”. Med. Cutan. Ibero Lat. Am., 1988, 16, 187.

[148] Conti M., Agarossi A., Parazzini F., Muggiasca M.L., Boschini A., Negri E. et al.: “HPV, HIV infection, and risk of cervicalintraepithelial neoplasia in former intravenous drug abusers”. Gynecol. Oncol., 1993, 49, 344.

[149] Spinillo A., Tenti P., Baltaro F., Piazzi G., Iasci A., DeSantolo A.: “Cervical intraepithelial neoplasia in pregnant intravenous drug users infected with human immunodeficiency virus type 1”. Eur. J. Obstet. Gyn. Reprod. Biol., 1996, 68, 175.

[150] Rezza G., Giuliani M., Serraino D., Branca M., Benedetto A., Garbuglia A. et al.: “Risk factors for cervical presence of human papillomavirus DNA among women at risk for HIV infection. DIANAIDS Collaborative Study Group”. Epidemiol. Infect., 1998, 121, 173.

[151] Goncalves M.A., Burattini M.N., Donadi E.A., Massad E.: “Risk factors associated with genital warts in HIV-positive Brazilian women”. Tumori, 2003, 89, 9.

[152] Dev D., Lo Y., Ho G.Y., Burk R.D., Klein R.S.: “Incidence of and risk factors for genital human papillomavirus infection in women drug users”. J. Acquir. Immune Defic. Syndr., 2006, 41, 527.

[153] Feingold A.R., Vermund S.H., Burk R.D., Kelley K.F., Schrager L.K., Schreiber K. et al.: “Cervical cytologic abnormalities and papillomavirus in women infected with human immunodeficiency virus”. J. Acquir. Immune Defic. Syndr., 1990, 3, 896.[154] Ho G.Y., Burk R.D., Fleming I., Klein R.S.: “Risk of genital human papillomavirus infection in women with human immunodeficiency virusinduced immunosuppression”. Int. J. Cancer, 1994, 56, 788.

[155] Branca M., Delfino A., Rossi E., Giacomini G., Leoncini L., Riti M.G. et al.: “Cervical intraepithelial neoplasia and humanpapillomavirus related lesions of the genital tract in HIV positive and negative women”. Eur. J. Gynaecol. Oncol., 1995, 16, 410.

[156] Serraino D., Napoli P.A., Zaccarelli M., Alliegro M.B., Pezzotti P., Rezza G.: “High frequency of invasive cervical cancer among female injecting drug users with AIDS in Italy”. AIDS, 1996, 10, 1041.

[157] Uberti-Foppa C., Origoni M., Maillard M., Ferrari D., Ciuffreda D., Mastrorilli E. et al.: “Evaluation of the detection of human papillomavirus genotypes in cervical specimens by hybrid capture as screening for precancerous lesions in HIV positive women”. J. Med. Virol., 1998, 56, 133.

[158] de Sanjose S., Valls I., Paz C.M., Lloveras B., Quintana M.J., Shah K.V. et al.: “Human papillomavirus and human immunodeficiency virus infections as risk factors for cervix cancer in women prisoners”. Med. Clin. (Barc.), 2000, 115, 81.

[159] Branca M., Garbuglia A.-R., Benedetto A., Leoncini L., Migliore G., Cappiello T. et al.: “Factors predicting the persistence of genital Human papillomavirus (HPV) infections and Pap smear abnormality in HIV-positive and HIV-negative women during prospective follow-up”. Int. J. STD & AIDS, 2003, 14, 417.

[160] Syrjänen K., Naud P., Derchain S.F., Roteli-Martins C., Longatto-Filho A., Tatti S. et al.: “Drug addiction is not an independent risk factor for oncogenic human papillomavirus (HPV) infections or high-grade CIN. Case control study nested eithin the LAMS Study cohort”. Int. J. STD & AIDS, 2007, In press.

[161] Shew M.L., Fortenberry J.D., Miles P., Amortegui A.J.: “Interval between menarche and first sexual intercourse, relatedto risk of human papillomavirus infection”. J. Pediatr., 1994, 125, 661.

[162] Kahn J.A., Rosenthal S.L., Succop P.A., Ho G.Y., Burk R.D.: “The interval between menarche and age of first sexual intercourse as a risk factor for subsequent HPV infection in adolescent and young adult women”. J. Pediatr., 2002, 141, 718.

[163] Moscicki A.B., Winkler B., Irwin C.E. Jr., Schacter J.: “Differences in biologic maturation, sexual behavior, and sexually transmitted disease between adolescents with and without cervical intraepithelial neoplasia”. J. Pediatr., 1989, 115, 487.[164] Syrjänen K.J., Shabalova I.P., Petrovichev N., Kozachenko V.P., Zakharova T., Pajanidi A. et al.: “Age at menarche is notan independent risk factor for high-risk Human Papillomavirus (HPV) infections and cervical intraepithelial neoplasia (CIN)”. Int. J. STD & AIDS, 2008, 19, 16.

[165] Burk R.D., Kelly P., Feldman J., Bromberg J., Vermund S.H., Dehovitz J.A. et al.: “Declining prevalence of cervicovaginalhuman papillomavirus infection with age is independent of other risk factors”. Sex. Transm. Dis., 1996, 23, 333.

[166] Kjaer S.K., van den Brule A.J., Bock J.E., Poll P.A., Engholm G., Sherman M.E. et al.: “Determinants for genital human papillomavirus (HPV) infection in 1000 randomly chosen young Danish women with normal Pap smear: are there different risk profiles foroncogenic and nononcogenic HPV types?”. Cancer Epidemiol. Biomarkers Prev., 1997, 6, 799.

[167] Melkert P.W., Hopman E., van den Brule A.J., Risse E.K., van Diest P.J., Bleker O.P. et al.: “Prevalence of HPV in cytomorphologically normal cervical smears, as determined by the polymerase chain reaction, is age-dependent”. Int. J. Cancer, 1993, 53, 919.

[168] Syrjänen K., Yliskoski M., Kataja V., Hippeläinen M., Syrjänen S., Saarikoski S., Ryhänen A.: “Prevalence of genital human papillomavirus (HPV) infections in a mass-screened Finnish female population aged 20-65 years”. Int. J. STD & AIDS, 1990, 1, 410.

[169] Syrjänen K., Hakama M., Saarikoski S., Väyrynen M., Yliskoski M., Syrjänen S. et al.: “Prevalence, incidence and estimated life-time risk of cervical human papillomavirus (HPV) infections in nonselected Finnish female population”. Sex Transm. Dis., 1990, 17, 15.

[170] Woodman C.B., Collins S., Winter H., Bailey A., Ellis J., Prior P. et al.: “Natural history of cervical human papillomavirusinfection in young women: a longitudinal cohort study”. Lancet, 2001, 357, 1831.

[171] Winer R.L., Lee S.K., Hughes J.P., Adam D.E., Kiviat N.B., Koutsky L.A.: “Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students”. Am. J. Epidemiol., 2003, 157, 218.

[172] Hildesheim A., Schiffman M.H., Gravitt P.E., Glass A.G., Greer C.E., Zhang T. et al.: “Persistence of type-specific human papillomavirus infection among cytologically normal women”. J. Infect. Dis., 1994, 169, 235.

[173] Herrero R., Hildesheim A., Bratti C., Sherman M.E., Hutchinson M., Morales J. et al.: “Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica”. J. Natl. Cancer Inst., 2000, 92, 464.

[174] Castle P.E., Schiffman M., Herrero R., Hildesheim A., Rodriguez A.C., Bratti M.C. et al.: “A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica”. J. Infect. Dis., 2005, 191, 1808.

[175] Munoz N., Mendez F., Posso H., Molano M., van den Brule A.J., Ronderos M. et al.: “Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results”. J. Infect. Dis., 2004, 190,2077.

[176] Lazcano-Ponce E., Herrero R., Munoz N., Cruz A., Shah K.V., Alonso P. et al.: “Epidemiology of HPV infection among Mexican women with normal cervical cytology”. Int. J. Cancer, 2001, 91, 412.

[177] Sellors J.W., Karwalajtys T.L., Kaczorowski J.A., Mahony J.B., Lytwyn A., Chong S. et al.: “Prevalence of infection with carcinogenic human papillomavirus among older women”. CMAJ, 2002, 167, 871.

[178] Anh P.T., Hieu N.T., Herrero R., Vaccarella S., Smith J.S., Thuy N.T. et al.: “Human papillomavirus infection among women in South and North Vietnam”. Int. J. Cancer, 2003, 104, 213.

[179] Baay M.F., Smits E., Tjalma W.A., Lardon F., Weyler J., Van Royen P. et al.: “Can cervical cancer screening be stopped at 50? The prevalence of HPV in elderly women”. Int. J. Cancer, 2004, 108, 258.

[180] Jacobs M.V., Walboomers J.M., Snijders P.J., Voorhorst F.J., Verheijen R.H., Fransen-Daalmeijer N. et al.: “Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types”. Int. J. Cancer 2000;87:221-227.

[181] Matos E., Loria D., Amestoy G.M., Herrera L., Prince M.A., Moreno J. et al.: “Prevalence of human papillomavirus infection among women in Concordia, Argentina: a population-based study”. Sex. Transm. Dis., 2003, 30, 593.

[182] Thomas J.O., Herrero R., Omigbodun A.A., Ojemakinde K., Ajayi I.O., Fawole A. et al.: “Prevalence of papillomavirus infection in women in Ibadan, Nigeria: a population-based study”. Br. J. Cancer, 2004, 90, 638.

[183] Peto J., Gilham C., Deacon J., Taylor C., Evans C., Binns W. et al.: “Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort”. Br. J. Cancer, 2004, 91, 942.

[184] Franceschi S., Herrero R., Clifford G.M., Snijders P.J., Arslan A., Anh P.T. et al.: “Variations in the age-specific curves of human papillomavirus prevalence in women worldwide”. Int. J. Cancer, 2006, 119, 2677.

[185] Syrjänen K.J., Shabalova I.P., Petrovichev N., Kozachenko V.P., Zakharova T., Pajanidi A. et al.: “Epidemiological, clinical and viral determinants of the increased prevalence of high-risk human papillomavirus (HPV) infections in elderly women”. Eur. J. Gynecol. Oncol., 2007, In press.

[186] Peitsaro P., Ruutu M., Syrjänen S., Johansson B.: “Divergent expression changes of telomerase and E6/E7 mRNA, following integration of human papillomavirus type 33 in cultured epithelial cells”. Scand. Infect. Dis., 2004, 36, 302.

[187] Peitsaro P., Johansson B., Syrjänen S.: “Integrated human papillomavirus type 16 is frequently found in cervical cancer precursors as demonstrated by a novel quantitative real-time PCR technique”. J. Clin. Microbiol., 2002, 40, 886.

[188] Kulmala S.M., Syrjänen S.M., Gyllensten U.B., Shabalova I.P., Petrovichev N., Tosi P. et al.: “Early integration of high copy HPV16 detectable in women with normal and low grade cervical cytology and histology”. J. Clin. Pathol., 2006, 59, 513.

[189] Holmes J., Hemmett L., Garfield S.: “The cost-effectiveness of human papillomavirus screening for cervical cancer. A review of recent modelling studies”. Eur. J. Health Econ., 2005, 6, 30.

[190] Ronco G., Giorgi-Rossi P., Carozzi F., Dalla P.P., Del M.A., De M.L. et al.: “Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial”. Lancet Oncol., 2006, 7, 547.

[191] Kitchener H.C., Almonte M., Wheeler P., Desai M., Gilham C., Bailey A. et al.: “HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial”. Br. J. Cancer, 2006, 95, 56.

[192] Wiley D.J., Monk B.J., Masongsong E., Morgan K.: “Cervical cancer screening”. Curr. Oncol. Rep., 2004, 6, 497.

[193] Baay M.F., Tjalma W.A., Lambrechts H.A., Pattyn G.G., Lardon F., Weyler J. et al.: “Combined Pap and HPV testing in primary screening for cervical abnormalities: should HPV detection be delayed until age 35?”. Eur. J. Cancer, 2005, 41, 2704.

[194] Agorastos T., Dinas K., Lloveras B., de S.S., Kornegay J.R., Bonti H. et al.: “Human papillomavirus testing for primary screening in women at low risk of developing cervical cancer. The Greek experience”. Gynecol. Oncol., 2005, 96, 714.

[195] Ronco G., Cuzick J., Segnan N., Brezzi S., Carozzi F., Folicaldi S. et al.: “HPV triage for low grade (L-SIL) cytology is appropriate for women over 35 in mass cervical cancer screening using liquid based cytology”. Eur. J. Cancer, 2007, 43, 476.

[196] Aubin F., Pretet J.L., Mougin C. (eds.): “Papillomavirus humains. biologie et pathologie tumorale”. Paris, Editions TEC & DOC, 2003, 1.

[197] Longatto-Filho A., Maeda M.Y.S., Erzˇen M., Branca M., Roteli-Martins C., Naud P. et al.: “Conventional PAP smear and liquid-based cytology as screening tools in low-resource settings of Latin America. Experience of the Latin American Screening Study”. Acta Cytol., 2005, 49, 500.

[198] Sarian L., Derchain S.M., Naud P., Roteli-Martins C., Longatto-Filho A., Tatti S., Branca M. et al.: “Evaluation of visual inspection with acetic acid (VIA), Lugol’s iodine (VILI) cervical cytology and HPV testing as cervical screening tools in Latin America. This report refers to partial results from the LAMS (Latin American Screening) study”. J. Med. Screen., 2005, 12, 142.

[199] Longatto-Filho A., Erzˇen M., Branca M., Roteli-Martins C., Naud P., Derchain S. et al.: “Human papillomavirus (HPV) testing as an optional screening tool in low-resource settings of Latin America. Experience from the LAMS study”. Int. J. Gynecol. Cancer, 2006, 16, 955.

[200] Hammes L.S., Naud P., Passos E., Rivoire W., Matos J., Brouwers K., Syrjänen K.J.: “Value of the International Federation of Colposcopy and Cervical Pathology (IFCPC) terminology in predicting cervical pathology”. J. Lower Genital Tract. Dis., 2007, 11, 158.

[201] Syrjänen K., Naud P., Derchain S.F., Roteli-Martins C., Longatto-Filho A., Tatti S. et al.: “Value of conventional Pap smear, liquid based cytology, visual inspection (VIA) and human papillomavirus (HPV) testing as optional screening tools among Latin American women below and above 35 years of age. Experience from the LAMS study”. Acta Cytol., 2008 (in press).

[202] Alonzo T.A.: “Verification bias-corrected estimators of the relative true and false positive rates of two binary screening tests”. Stat. Med., 2005, 24, 403.

[203] Woodman C.B.J., Collins S.I., Young L.S.: “The natural history of cervical HPV infections: unresolved issues”. Nature Rev. Cancer, 2007, 7, 11.

[204] dos Santos Silva I.: “Cancer epidemiology: principles and methods”. IARC, Lyon, 1999, 355.